Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
NEW YORK, NY - (NewMediaWire) - February 05, 2024 - Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“the Company”), is pleased to announce its CEO and President, Dr. Milton Werner, recently interviewed with SmallCapsDaily discussing the Company's innovative approach in neurodegenerative disease treatment. Dr. Werner highlighted the significant progress of Inhibikase's lead candidate, Risvodetinib, in its Phase 2 trial for Parkinson's disease, emphasizing the potential to alter the course of disease. He also shed light on Inhibikase Therapeutics' commitment to addressing unmet medical needs and its broader strategy in neurological conditions.
To read the full interview visit: https://smallcapsdaily.com/smallcaps-daily-sits-down-with-milton-werner-president-and-ceo-of-inhibikase-therapeutics
About Inhibikase Therapeutics, Inc:
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program Risvodetinib, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with an office in Lexington, Massachusetts.
For more information, please visit: https://profiles.smallcapsdaily.com/ikt